Pharmaceuticals

After a strategic reset, Australian biopharma Immuron reports record sales and a stronger cash position, pivoting to partner its high-value drug candidates.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

An Argentine firm is scaling up to challenge global pharma giants, promising a more stable supply of a critical drug and a new model for trust in medicine.

Xeris Biopharma's XP-8121 aims to solve a key problem in hypothyroidism. Can this weekly injection capture a multi-billion dollar market from daily pills?

A new FDA petition aims to slash drug development costs for copies of even the most complex medicines. Is this the key to global access or a threat to innovation?

A landmark $1.5B+ deal for a Chinese drug marks a major global shift. Haisco's innovative partnership with a US venture is reshaping biotech collaboration.

The American Botanical Council is making a high-stakes play to rebrand coca. Can a strategic campaign of science and media finally sever the link to cocaine?

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

Takeda's ORZEYFUL, a first-in-class orexin agonist, wins approval in Japan, offering the first treatment for the root cause of Narcolepsy Type 1.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

A 645% surge in contracts is just the headline. The real story is how NetraMark's 'explainable' AI is building trust and changing how we develop new cures.

As AI becomes mission-critical in life sciences, a new mandate emerges: prove it's governed. A look at the shift from adoption to inspection-ready AI.

A new campaign in Newfoundland challenges federal rules, asking why quitting aids are harder to buy than cigarettes, and exposing a booming black market.

A new campaign pressures NB's government to fight federal rules limiting nicotine pouches to pharmacies, igniting a debate on rural access and harm reduction.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

A groundbreaking clinical trial is testing whether a common bone-strengthening drug can 'unmask' and eliminate the hidden HIV reservoir, a critical barrier to a cure.